Key molecular targets in NAFLD development include ChREBP, free fatty acids (FFAs), glucagon-like peptide 1 (GLP-1), interleukins (IL), nuclear factor κB (NF-κB), peroxisome proliferator-activated receptor γ (PPAR-γ), reactive oxygen species (ROS), sterol regulatory element binding protein (SREBP-1c), and tumor necrosis factor (TNF-α) [2]. Here, SREBF1 is linked to metabolic dysfunction-associated steatotic liver disease.